Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

この論文にアクセスする

抄録

Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases. The anti-tumor effect of sorafenib is thought to be mediated through its inhibition of the RAS-Raf-Erk pathway, as well as its inhibition of VEGFR and PDGFR. Sorafenib has been effective at treating patients with renal cell carcinoma (RCC). Ovarian clear cell carcinoma (OCCC) is a chemoresistant subtype of ovarian cancer. OCCC is represented by cells with clear cytoplasm that resemble those observed in RCC. Using a microarray database, the gene expression profile of OCCC was similar to that of RCC. The effects of sorafenib against human OCCC are unknown. Therefore, we used sorafenib to treat two patients with recurrent chemoresistant OCCC, and observed good effect in both of them without severe side effects. We believe that sorafenib is an effective agent against OCCC. Given the chemoresistant nature of this tumor, this drug appears to be very valuable.

収録刊行物

  • Cancer biology & therapy

    Cancer biology & therapy 15(1), 22-25, 2014-01-01

    Landes Bioscience

各種コード

  • NII論文ID(NAID)
    120005367800
  • 本文言語コード
    ENG
  • 資料種別
    journal article
  • ISSN
    1538-4047
  • データ提供元
    IR 
ページトップへ